Study Title
Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis
Protocol ID
ANHL2121
Condition/s
Recurrent Langerhans Cell Histiocytosis
Refractory Langerhans Cell Histiocytosis
Refractory Langerhans Cell Histiocytosis
Diagnosis Stage
Progressive, Relapse, or Refractory
Location
NSW, VIC, WA
Sponsor
Children's Oncology Group
Links
Trial Status
Preparing to Open
Sites
Perth Children's Hospital
Sydney Children's Hospital
The Royal Children's Hospital
Sydney Children's Hospital
The Royal Children's Hospital
Study Type
Treatment
Phase
Phase 2
Age Eligibility
Up to 22 Years
International registry ID's
NCT05828069
| Study Title | Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis |
|---|---|
| Protocol ID | ANHL2121 |
| Disease (Sub Disease) | Recurrent Langerhans Cell Histiocytosis Refractory Langerhans Cell Histiocytosis |
| Diagnosis Stage | Progressive, Relapse, or Refractory |
| Location | NSW / VIC / WA |
| Sponsor | Children's Oncology Group/ |
| Links | https://clinicaltrials.gov/study/NCT05828069 |
| Trial Status | Preparing to Open |
| Sites | Perth Children's Hospital / Sydney Children's Hospital / The Royal Children's Hospital/ |
| Study Type | Treatment |
| Phase | Phase 2 |
| Age Eligibility | Up to 22 Years |
| International registry ID's | NCT05828069 |